HLA disparity between hematopoietic stem cell (HSC) donor and recipient triggers T-cell and NK-cell allorecognition, and induces the GVHD, GVL effect and/or may cause an engraftment failure. This review will cover the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. We describe the main subsets of related and unrelated HSC donors and outline the main aspects of HLA disparity and their effect on the outcome of the patients after allogeneic HSC transplantation (HSCT). The HLA match between HSCT donor and recipient is crucial, but for many patients a perfectly matched donor is not available. The HSCT from the alternative mismatched donor with one allele/antigen mismatch (9/10) can be as beneficial as a HSCT from a fully matched donor, especially in younger patients. For the remaining patients, the donors with permissive mismatches may be the option. The permissiveness depends not only on the potential adverse effect of the HLA mismatches, but also on the urgency of the transplantation, the desirable GVL effect and the potential efficacy of the alternative therapy available for the patient.
Introduction
Normal human genomic variations may generate potentially immunogenic transplantation antigens and cause GVHD, GVL reaction or graft rejection in the course of hematopoietic SCT (HSCT). Two particular individuals, such as hematopoietic stem cell (HSC) donor and recipient, always differ in their genome structure, minor histocompatibility antigens, killer cell immunoglobulin-like receptor (KIR) genes and/or several other groups of genes (see Table 1 ). 1 However, the most potent transplantation antigens are HLAs encoded by genes located in MHC.
HLAs possess outstanding ability to elicit an immune response either by presentation of variable peptides or by recognition of polymorphic fragments of foreign HLA molecules. In the future, evaluation before HSCT is likely to comprise a more detailed genetic analysis of patient and donor, but currently the standard is HLA typing at A, B, C, DRB1 and DQB1 genetic loci. The importance of HLA-DPB1 donor-recipient matching is still under debate and HLA-DRB3/4/5 testing targets to the class II haplotype matching surpassing current standards as well.
Methods of HLA typing and presentation of the results
There are various modifications of DNA-based HLA typing methods. Thus, sequence-specific oligonucleotide probe hybridization, sequence-specific primer amplification, sequencing-based typing and reference strand-based conformation analysis methods with several modifications are most frequently used. As a preliminary or supportive one, the serology-based method (lymphocytotoxicity test by Terasaki in National Institutes of Health modification or fluorescent test) is still in use, especially to clarify the absence of some null alleles or to narrow down the array of primers or probes to be used in confirmatory DNA-based tests.
The presentation of the genotyping results of the HLA allele can be of low (two digit: for example, A*01), high (four or more digits: for example, B*1302) or intermediate resolution (several ambiguous alleles belonging to one lowresolution group separated by a slash: for example, DRB1*0401/03/04/08). The notation of an ambiguous result can be abbreviated by NMDP codes. 2 In the latest example, an ambiguous result is abbreviated as DRB1*04EX. The ambiguity is a consequence of high levels of homology of different groups of alleles. As a result, it is frequently seen that those tests claimed to be 'high-resolution tests' actually gave the results at the intermediate-resolution level.
To solve the problem of unwieldy additional testing demanded sometimes by transplant physicians wishing to achieve unambiguous results, a subset of ambiguities has been defined that almost always resolves into the genotype with the most common allele. The study of Cano et al. 3 was conducted on a big sample of more than 25 000 patients and provided the definition of common and well-documented (CWD) alleles. The list of CWD alleles in each locus (see Table 2 ) is restricted to 26-33% of the total number of HLA alleles. It is accepted by American Society of Histocompatibility and Immunogenetics that high-resolution typing result for one individual may contain only one multiple ambiguous genotype, if it contains one (for homozygotes) or two (for heterozygotes) CWD alleles in each locus. 3 All alternative genotypes, except 'rare-rare' genotypes that could not be excluded by direct typing, have to be resolved by additional typing. For such level of highresolution typing, the two-CWD allele genotype is on average 1000-10 000 times more probable than 'rare-rare' genotype. Furthermore, it is accepted by American Society of Histocompatibility and Immunogenetics and European Federation for Immunogenetics that high-resolution results may contain ambiguous descriptions produced by nucleotide substitutions outside the antigen recognition site (ARS) domains, because they seem to be not valid for HSCT outcome. The combined criterion of the 'maximum one genotype with up to two CWD alleles plus non-ARS substitutions' seems to be a reasonable basis for clinical histocompatibility decisions. Using these criteria, HSCT donor matching at the high-resolution level can be achieved much more rapidly, which is of clinical importance 4 in the time pressure era when acute leukemia is most frequently diagnosed in HSCT recipients. 5 The final HLA results should always include all ambiguous alleles that could not be excluded by direct typing. This implies that high-resolution HLA results need an explanatory comment with the information that they meet 'one genotype with up to two CWD plus non-ARS' high-resolution criteria when they have a presentation of ambiguous intermediate resolution.
HSCT donors
The optimal HSCT donor is a sibling of the patient who is identical in both alleles of each of the HLA-A, B, C, DRB1 and DQB1 loci. We call this donor the '10/10 allele match' or perfect match. This kind of donor (or family cord blood unit) is available for 15-30% of patients depending on the number of children in families. Generally, always (when parents are available) the HLA familiar study at the lowresolution level (or two-digit level) should be performed unless homozygosity is expected in the family; in this case, the four-digit typing of the donor recipient pair must be performed. Both typings should be confirmed by duplicate typing performed in the second sample drawn independently to show reproducibility of results (that is, the absence of clerical and technical errors). For those patients who have no family donor, a good option can be a perfectly matched (10/10 HLA alleles) unrelated donor. This kind of donor is available for 30-70% of patients, 5 depending on the frequency of the HLA genotype in registry donors and the ethnicity of the patient. In the unrelated donor search process, high-resolution (four-digit) genetic typing of both patient and donor is necessary and confirmation of the results is obligatory. All remaining patients in need of allo-HSCT (15-50%) are dependent on the alternative donors, which in this paper means different degrees of HLA incompatibility of these donors.
Three main subsets of alternative donors are haploidentical family donors (5-9/10 alleles matched), partially mismatched (or fully matched in rare cases) unrelated cord blood units (3-6/6 alleles matched in A, B and DRB1 loci) and partly mismatched unrelated donors (UDs; 7-9/10 alleles matched). Only these mismatched donors with permissive mismatches should be accepted by transplant physicians for HSCT, but the definition of permissiveness is a matter of permanent debate. The adverse HLA effect on the outcome depends on the total number of mismatched alleles, locus of the mismatch and the resolution level of the mismatch (antigenic or allelic level). The transplant outcome may be further influenced by the location of the amino acid substitutions in or out of ARS of the HLA molecule. The ARSs are the structures that directly bind peptide and T-cell receptor. For HLA class I molecules, these important ARS structures are restricted to the a1 and a2 domains (encoded by exons 2 and 3 of the HLA class I heavy chain gene) and for class II molecules to the b2 domain (encoded by exon 2 of the HLA class II b chain gene). The number of amino acid substitutions and even amino acids substituted in specific positions within the HLA molecule can also be important. The KIR ligation diversity between the donor and recipient arises from the differences between HLA class I KIR-binding specificity and affinity. This KIR ligation diversity is thought to influence the transplant outcome as well. Some indirect data imply that the MHC haplotype match is important for HSCT outcome considering their regulation at the transcriptional level by chromosomal domain effect. 6 Being described as risk factors for the transplantation outcome, all these types of HLA incompatibility can be balanced with the alternative methods of therapy available for the patient. The beneficial GVL effect also depends on HLA mismatch. 7 The effect is easily observed but its mechanism is not fully understood and it is difficult to keep a balance between GVL and deleterious high-grade GVHD. The broad scope of HLA variability at different levels makes it extremely difficult to select homogeneous patient groups that are large enough for reliable outcome comparisons.
Effect of HLA disparity on HSCT
Perfectly matched related (MR) donors, predominantly siblings, are better than mismatched-sibling donors and UDs grouped together. [8] [9] [10] [11] The recipients of stem cells from MR donors have lower risk of infections, 8, 9 of cytomegalovirus (CMV) reactivation 10 and of mortality 11 than the latter group (for statistical significance and details of different HLA disparities, see Table 3 ). The T-cell immunity reconstitution is delayed in the mismatchedsibling donors and UD group. 12 After 1998, when better HLA typing methods replaced DNA fingerprinting, serology and low-resolution methods used for final donor matching the overall survival (OS) of transplant patients has improved greatly. 13 However, better transplant procedures and effective rescue of patients relapsing after HSCT might favorably influence the transplant outcome as well. 14 In contrast, OS, EFS, transplantation-related mortality, relapse and high-grade acute GVHD rates after HSCT from precisely typed perfectly matched UDs reach levels comparable to the classical MR donors. 15 These similarities in outcome suggest that well selected UDs can perform as well as MR donors 15 or even better in older patients. 23 All these findings only indirectly suggest the role of the HLA disparity in impaired transplant outcome.
The direct assessment of the number of HLA mismatches between the donor and the recipient has shown its great importance in UD SCT. It was clearly confirmed by large (N ¼ 2399 donor-recipient pairs) multicenter multivariate data analysis performed during the 13th International Histocompatibility Workshop and Conference (IHWC). In the patients after myeloablative HSCT, the OS was significantly worsened when single allele/antigen mismatched (9/10) transplants were used as compared with perfectly matched (10/10) transplants. 16 After HSCT from UDs with two and more than two mismatches, the OS has shown further systematic deterioration in the respective patient groups. 16 However, the administration of antithymoglobuline (ATG) combined with the standard immunosuppression regimen may lead to similar acute GVHD incidence in patients transplanted from the donors with 1 A, B, DRB1 or DQB1 allele/antigen mismatched and 8/8 allele match. 24 In children with leukemia, a similar regimen produced acceptable EFS and OS after transplantations from 7-8/10 mismatched UDs. 17 The 13th IHWC multicenter data could be analyzed also for the importance of each particular HLA locus separately, showing the independent deleterious effect only for C, B and DRB1 loci, at least for donor-recipient pairs of European ancestry. 16 Differently, for Japanese donorrecipient pairs, the independent deleterious effect of A, B and DRB1, but not C locus, has been shown in multivariate analysis. 16 The interpretation of this ethnical difference is difficult. The Japanese data were less numerous, containing 10% of the donor-recipient pairs studied, but there is no evidence about lower reliability of these data. In a separately published analysis of the HLA-A2 allele group in 14th IHWC cohort, 25 only A*0201/A*0206 allele mismatch (the typical one for Japanese group) showed a significantly elevated risk of mortality. For all remaining A2-group allele mismatches, no significant effects have been revealed, including A*0201/A*0205 mismatch, the most frequent one in a non-Japanese group. In total, the mismatches form a specific subgroup of alleles of low frequency. 26 Strong linkage disequilibrium observed along with the whole MHC genetic system 27 suggest that the extensive haplotypic disparity exists between recipients and mismatched donors. HLA haplotypes are known to be ethnically specific to a wider extent than alleles. 28 Therefore, it is intriguing whether the haplotype level of HLA disparity is also effective for the HSCT outcome.
The level of HLA disparity (antigenic or allele level) affects differently the HSCT outcome.
18-20 Single HLA class I allele level disparity had no significant impact on OS. 18 The sequence analyses show that the antigenic disparity is frequently associated with more than 10 amino acid substitutions in the HLA molecule. This difference at the molecular level represents a clear structural distinction that can be easily recognized by immunocompetent cells, and thus it can stimulate immune response. 18 The allele level disparity most frequently concerns only one or a few amino acid substitutions. This should produce weaker immune stimulation. It was coherently shown for cord blood unit transplantations in pediatric patients that there was no deleterious effect of allele level mismatch. 19 This idea should be compiled in greater detail with the observation of Heemskerk et al. 20 that highly diverged MHC mismatches, with more than five amino acid substitutions in each of the a and b structures of class I molecules with negative cytotoxic T lymphocyte precursors frequencies, are better tolerated than less diverged grafts. Similarly, the linear increase of the number of amino acid substitutions in the disparate HLA molecule may cause the significant deleterious effect 29 or be irrelevant 18 in HSCT. The specific location of amino acid substitution has been announced by Ferrara et al. 29 to be effective, with a special adverse role of the amino acid substitution in position 116 of the HLA molecule. Further, a detailed study revealed in this position that only directional substitutions of asparagine to aspartic acid and leucine to serine in A and C molecules, respectively, were adversely effective in Japanese donor-recipient pairs. 30 These particular substitutions were most frequent in Japanese 30 but completely absent in Table 3 Significance of HLA disparity in HSCT European mismatched donor-recipient pairs. 31 In aggregate, these conflicting or population-dependent findings at the HLA molecular level uncovered an urgent need of the search for a more general explanatory mechanism.
HLA class I molecules are ligands of KIR, the receptors of NK cells. Depending on the type of KIR, the ligation by HLA can stimulate or inhibit the ability of NK cells to kill foreign cells, including tumor cells. 32 Giebel et al. 33 detected significantly better survival in patients with the KIR ligand type HLA incompatibility than in those with either fully matched or partially mismatched UDs, but others did not confirm this finding. 21 The strong immune reactions provoked by the T-cell recognition elements on incompatible HLA molecule can probably override the favorable effect of the simultaneous KIR ligand mismatch. 22 The coexistence of the incompatibility of both types on the same HLA molecule makes it difficult to show clearly the advantage of the KIR ligand mismatch and hampers the selection of appropriate donors.
The deleterious effect of a given HLA mismatch was more strongly expressed in the patients with low rather than high-risk disease. 34 For patients without a perfect donor, it is sometimes a better option to accept a partly mismatched or haploidentical HSCT donor rapidly than to extend the search beyond the optimal phase of the disease. 4 
Conclusions
The HLA matching between the HSCT donor and recipient is crucial, but for many patients a perfectly matched donor can be unavailable. The HSCT from the alternative mismatched donor with one allele/antigen mismatch (9/10) can be as beneficial as HSCT from a perfectly matched donor, especially in younger patients. For the remaining patients, the donors with permissive mismatches may be the option. The permissiveness depends not only on the potential adverse effect of the HLA mismatches, but also on the urgency of the transplantation, the desirable GVL effect and the potential efficacy of the alternative therapy available for the patient.
